arGentis acquires rights to rheumatoid arthritis therapy
This article was originally published in Scrip
Executive Summary
The privately held biopharmaceutical company arGentis Pharmaceuticals is to collaborate with the University of Tennessee Health Science Center (UTHSC) and the Veterans Affairs Medical Center (VAMC) of Memphis to progress the oral altered peptide ligand (APL), ARG301, into a Phase I study in rheumatoid arthritis patients.